Related Articles
Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway
Amplification of mutant <em>KRAS</em><sup>G12D</sup> in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report
Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG‑510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL‑XL
c‑Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer
Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome